Asoprisnil
Jump to navigation
Jump to search
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C28H35NO4 |
Molar mass | 449.591 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Asoprisnil (INN; developmental code name J-867) is a synthetic, steroidal selective progesterone receptor modulator that was under development by Schering and TAP Pharmaceutical Products for the treatment of uterine fibroids.[1] In 2005, phase III clinical trials were discontinued due to endometrial changes in patients.[2]
See also
References
- ^ DeManno D, Elger W, Garg R, et al. (2003). "Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy". Steroids. 68 (10–13): 1019–32. doi:10.1016/j.steroids.2003.09.008. PMID 14667995. S2CID 23074350.
- ^ Schering Interim Report Q1-3 2005
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- Articles with changed CASNo identifier
- Chemical pages without DrugBank identifier
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Antiglucocorticoids
- Estranes
- Experimental drugs
- Enones
- Aldoximes
- Selective progesterone receptor modulators
- All stub articles
- Antineoplastic and immunomodulating drug stubs